ATECAlphatec Holdings, Inc.
The Read
ATEC’s stock fell sharply after 2025 earnings due to slowed growth guidance, plunged further on heavy insider selling despite market share gains, crashed again amid securities fraud probes and institutional selling, but later rallied modestly as the market dismissed the fraud investigation’s impact.
The schedule
- Wed23Sep
At the critical North American Spine Society (NASS) meeting, Alphatec will showcase its surgical solutions. Starting from an assumed $7.80, a strong reception pushes shares to $9.50, while poor traction sees a $6.50 fallback.
- Thu29Oct
Q3 2026 earnings will test whether recent product momentum translates to narrowing operating losses. From a $9.50 base, strong margins support an $11.50 target, whereas cash burn concerns floor the stock at $7.50.
- Thu10Dec
With cash balances drawn down and debt remaining elevated, ATEC may provide a liquidity update. From $7.50, non-dilutive refinancing lifts the stock to $8.80, but a dilutive raise drops it to $5.50.
- Tue9Feb
The Q4 print and initial 2027 guidance will reset long-term growth expectations. Assuming a $5.50 entry, strong 2027 revenue targets push shares to $7.20, while a growth deceleration tanks the stock to a $4.00 deep fundamental floor.
- Tue4May
First quarter 2027 results will dictate early momentum for the fiscal year. Anchored at $4.00, achieving operating leverage sparks a recovery to $5.50, but lingering net losses drag shares to $3.00.
Past
- Thu30Jul
Actual outcome: Bear · $9.31 at outcome
Alphatec reported Q2 revenue of $214 million, up 15% year-over-year, alongside positive free cash flow and higher profitability. However, earnings lagged consensus estimates, leading to a muted market reaction that left the stock relatively flat as it failed to break out toward either the bull target or the bear floor.
Alphatec will report its Q2 2026 results amidst severe governance overhangs and heavy debt loads. With spot price at $9.51, a favorable resolution clears the air toward $11.00, while a miss drives shares to $7.80.
- Sun26Jul
Actual outcome: Bull · $7.52 at outcome
Stock fell 13.3% from event to outcome date, aligning with the bull trajectory.
Stock fell 13.3% from event to outcome date, aligning with the bull trajectory.
- Tue30Jun
Actual outcome: Bull · $9.33 at outcome
The stock rallied 7.9% through the outcome date, easily surpassing the $9.00 bull target. The market largely dismissed the announcement of a class-action securities fraud investigation by Johnson Fistel as immaterial, allowing shares to maintain their upward trajectory.
- Tue5May
Actual outcome: Bear · $6.99 at outcome
Alphatec reported Q1 earnings that met EPS estimates alongside a new debt refinancing facility, but the stock plummeted over 30% following the release. The severe sell-off was driven by institutional dumping and the subsequent announcement of multiple securities fraud investigations concerning potentially inaccurate statements about the company's financials and operations, pushing shares well below the bear floor.
- Sun15Mar
Actual outcome: Bear · $10.43 at outcome
The stock fell 17.2% and broke well below the $16.00 bear floor, driven by significant insider selling pressure. Despite management touting market share gains and improving cash flow at an industry conference, the COO offloaded over $3.2 million in stock shortly after. This heavy insider liquidation exacerbated negative sentiment and confirmed the valuation reset risk, driving the stock sharply lower.
- Tue24Feb
Actual outcome: Bear · $13.47 at outcome
While Alphatec reported a beat on Q4 2025 revenue and earnings, the stock fell significantly because management issued 2026 guidance that signaled a moderate deceleration in growth. This outlook overshadowed improvements in cash flow and profitability, leading investors to re-rate the stock downward as the path to justifying its high-growth valuation became less certain.
